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Clinical Case Report
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Venous thromboembolism related
to cytomegalovirus infection
A case report and literature review
∗

Amar H. Kelkar, MDa, , Kavitha S. Jacob, MDa, Eman B. Yousif, MDb, John J. Farrell, MDc
Abstract
Rationale: Herein, we present a case of seemingly unprovoked portal vein thrombosis (PVT) occurring in the context of an acute

cytomegalovirus (CMV) infection and prolonged debilitating fatigue.
Patient concerns: A 46-year-old male airline pilot presented with a 2 week history of abdominal pain, nausea, vomiting, watery
diarrhea, and daily recurrent fevers. This was in the context of progressive, debilitating fatigue for 3 months forcing the patient to leave
his job.
Diagnoses: Computed tomography of the abdomen revealed PVT, which was managed initially by heparin infusion. Cefepime was
ordered for broad-spectrum antibiotic management of sepsis and possible septic thrombosis. Further workup exposed elevated
transaminases consistent with mild hepatitis without synthetic dysfunction and colonoscopy revealed colitis. A comprehensive
evaluation for liver disease was notable for a markedly elevated ferritin level. Spiking fevers and neutrophilia persisted for several days
despite empiric antimicrobial treatment, but eventually resolved. The remainder of the workup was negative except for positive CMV
IgM titer and viral load. This raised suspicion for a hypercoagulable state caused by CMV hepatitis with CMV-induced PVT. Heparin
was transitioned to warfarin at the time of discharge.
Interventions: Given the patient’s immunocompetent state and resolution of fevers, antiviral therapy for CMV infection was not

initiated.
Outcomes: The patient continued to improve with a normalization of the serum ferritin level and anticoagulation therapy was
stopped after 6 months.
Lessons: There is mounting support for infectious causes of venous thromboembolism (VTE) based on existing molecular biology
and clinical research. Meta-analysis of existing data showed that between 1.9% and 9.1% of patients hospitalized with VTE had
concurrent acute CMV infection. Theoretical mechanisms for this association include transient formation of antiphospholipid
antibodies, transient formation of antibodies targeting CMV capsule phospholipids with procoagulant properties, and direct infection
of the endothelial cells. We hope this case will serve as a reminder to consider CMV as a transient cause of PVT and VTE, particularly in
light of 2016 guidelines for unprovoked VTE recommending lifelong anticoagulation. We also plan to prospectively study the
association of unprovoked VTE and acute CMV infection in our own hospital system.
Abbreviations: b2GPI = beta-2-glycoprotein I, APS = antiphospholipid syndrome, CMV = cytomegalovirus, PVT = portal vein

thrombosis, VTE = venous thromboembolism.
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1. Introduction
Editor: Ewa Janczewska.

Unprovoked venous thromboembolism (VTE) is a common
diagnosis, resulting in thousands of patients being placed on
anticoagulation without a clear understanding of the underlying
cause of coagulopathy. In such cases, cytomegalovirus (CMV) is
rarely considered as a possible provoking agent; however, there is
emerging data supporting its role as a cause of a transient
hypercoagulable state. Herein, we present a case of CMVinduced portal vein thrombosis (PVT) along with a literature
review of similar cases.
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2. Case history
A 46-year-old male airline pilot presented as a regional transfer to
our facility with progressive abdominal pain for the prior 2
weeks. This was further characterized as a stabbing periumbilical
pain associated with nausea, vomiting, watery diarrhea, and
recurrent daily fevers over the same period of time. Further
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(Fig. 1A, B). This was conﬁrmed by abdominal ultrasound with
portal vein duplex showing retrograde ﬂow and a visible
thrombus with normal echogenicity of the liver. With persistent
fevers and concern for septic thromboembolism, continuous
heparin infusion and intravenous cefepime antibiotic therapy (2 g
every 8 hours) were initiated on arrival. Further evaluation for
liver disease revealed a ferritin level of 6248 ng/mL (Table 2),
which was not accompanied by any other clinical or laboratory
evidence of hemochromatosis. Additional workup for liver
disease revealed moderately low alpha-1-antitrypsin levels,
though the patient did not display other classic signs of the
disease.
As the workup progressed, the patient continued to have daily
fever spikes and neutrophilia, despite empiric antimicrobial
treatment and negative blood and stool cultures (Table 3).
Testing for human immunodeﬁciency virus was negative;
however, the remainder of the evaluations for both fever and
hepatitis revealed a positive CMV IgM titer and abnormal
hepatitis B and C ﬁndings. Viral loads for both hepatitis viruses
were negative, but CMV viral titers were markedly elevated,
supporting the diagnosis of an active CMV infection. On hospital
day 5, fevers ceased and did not recur. The patient was
transitioned from heparin to warfarin for discharge.
The diffuse nature of our patient’s disease processes with
objective ﬁndings of pathology in both the liver and colon, in
addition to the PVT, strongly suggested CMV was the underlying
etiologic agent. This ﬁt with the history of a viral prodrome along
with the ﬁnding of atypical lymphocytes in the peripheral smear.
However, due to his immunocompetent state and resolution of
fevers, we did not favor antiviral therapy for the CMV infection
at the time of discharge.

history revealed that the patient had been out of work for 3
months due to progressive, debilitating fatigue. Watery diarrhea
was occurring approximately twice daily without any associated
weight loss. Earlier in the week, the patient had been treated
empirically by his primary care physician with a course of
azithromycin without any improvement. Social history was not
signiﬁcant, as the patient did not smoke cigarettes, use other
tobacco products, or use illicit drugs. In addition, he had avoided
alcohol for most of his life due to his profession as a pilot. The
patient was unmarried and had not been sexually active in several
years. Past medical history was similarly noncontributory, as the
patient denied having any known chronic conditions or
prolonged hospitalizations and denied taking any medications
or supplements. His family history was only signiﬁcant for
Hashimoto disease in his mother, sister, and maternal aunt.
Physical examination was notable for a fever of 38.6 °C,
tachycardia averaging 105 beats per minute, and abdominal
tenderness to deep palpation of the periumbilical area and the
right upper quadrant. The liver span was 13 cm at the
midclavicular line by percussion, suggestive of mild hepatomegaly. He did not have any notable rash, lymphadenopathy,
palpable splenomegaly, or any other stigmata of liver disease.
There were also no warm, swollen, tender, or immobile joints
upon musculoskeletal examination.
Initial laboratory ﬁndings were consistent with mild hepatitis
with elevated transaminases, mild hyperbilirubinemia, and mild
hypoalbuminemia without coagulopathy or hyperammonemia
(Table 1). The patient also had mild hyponatremia, elevated Creactive protein, and elevated lactate dehydrogenase levels. The
initial blood counts showed mild neutrophilia, atypical lymphocytes, and rare smudge cells. Prior to transfer, computed
tomography of the abdomen with contrast revealed PVT

3. Differential diagnosis
Table 1

As part of the initial evaluation, the differential diagnosis for the
fever was considered in the context of watery diarrhea and
thrombosis. Prior to admission, workup for his fevers had
included complete blood counts, a metabolic panel, chest X-ray,
urinalysis, and urine cultures. He also received empiric therapy
with azithromycin. Without a proven infectious source on those
studies, we ﬁrst focused on infectious diarrhea and bacteremia;
however, all cultures resulted negative. Other causes such as
pharyngitis, cholecystitis, and intraabdominal abscess were ruled
out by physical examination and imaging studies. Septic
thrombus was also considered unlikely due to the lack of
positive blood cultures. As these ﬁndings returned negative, and
he approached the 3-week mark of fevers, fever of unknown
origin was more strongly considered. Drug-induced fever was
considered unlikely due to the lack of any medications or
supplements being taken prior to the onset of fevers. Before the
consideration of rarer causes, such as tuberculosis or parasitic
infections, several viral infections were tested.
This paired well with a similar ongoing work-up for hepatitis.
The patient had mild, but new and persistent transaminitis and
hyperbilirubinemia without evidence of synthetic liver dysfunction. In the context of PVT, our gastroenterology consultant
recommended evaluation for underlying liver disease and they
proceeded with a colonoscopy to evaluate for colitis due to the
persistent diarrhea. Hyperferritinemia was notable, but was an
isolated feature. This ruled out hemochromatosis and many
autoimmune conditions, such as adult Still disease due to the lack
of arthralgias, rash, or pharyngitis. As mentioned above, the
alpha-1-antitrypsin level was also noted to be low, so

Initial laboratory studies.
Study

Value

Normal range

Sodium
Potassium
CO2, venous
Creatinine, blood
Lactic acid
Total bilirubin
Direct bilirubin
Alkaline phosphatase
Aspartate aminotransferase
Alanine aminotransferase
Gamma glutamyl transferase
Total protein
Albumin
Ammonia
International normalized ratio
Partial thromboplastin time
Fibrinogen
White blood cell

134 mmol/L
4.0 mmol/
23 mmol/L
0.76 mg/dL
1.6 mmol/L
1.6 mg/dL
0.7 mg/dL
150 U/L
90 U/L
148 U/L
117 U/L
6.1 g/dL
3.1 g/dL
30 mmol/L
1.1
35 sec
236 mg/dL
11.79 cells per microliter

Absolute neutrophil count

8.25 cells per microliter

Hemoglobin
Platelet

15.6 g/dL
144 platelets
per microliter
7.05 mg/dL
2 mm/h
577 U/L
<10 mg/dL

136–145 mmol/L
3.5–5.1 mmol/L
22–30 mmol/L
0.70–1.30 mg/dL
0.7–2.1 mmol/L
0.2–1.2 mg/dL
0.0–0.5 mg/dL
40–150 U/L
5–34 U/L
0–55 U/L
12–64 U/L
6.3–8.2 g/dL
3.5–5.0 g/dL
18–72 mmol/L
0.9–1.2
24–36 sec
185–475 mg/dL
4.00–12.00 cells
per microliter
1.40–5.30 cells
per microliter
13.0–16.5 g/dL
140–440 platelets
per microliter
<0.50 mg/dL
0–15 mm/h
125–220 U/L
<10 mg/dL

CRP
Erythrocyte sedimentation rate
Lactate dehydrogenase
Ethanol
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Figure 1. The arrows point to hypoattenuated areas that represents parts of the thrombus: (A) this image depicts the portal vein thombus in the extra-hepatic portal
vein; (B) this image depicts the portal vein thombus at branchpoint to the anterior right main portal vein. These images were generated by computed tomography of
the abdomen and pelvis, performed with intravenous contrast dye.

chain reaction. This was supported by the ﬁnding of
approximately 10% atypical lymphocytes noted on the
peripheral smear after admission. We suspect that the CMV
infection was responsible for viral hepatitis, which caused PVT,
and colitis, which caused watery diarrhea. When considering
the elevated CMV IgG titer in the setting of detectable CMV
viremia, these ﬁndings are consistent with a chronic active
infection that would account for the chronic fatigue-like
syndrome exhibited by our patient.

phenotyping was sent, revealing an SZ phenotype. This is
associated with a low alpha-1-antitrypsin level without always
carrying the classic disease presentation of the ZZ phenotype.
For a number of reasons, including a viral pattern of the
transaminases, viral hepatitis was the favored etiology. Both
hepatitis B and C had somewhat abnormal antibody testing,
but proved negative on polymerase chain reaction testing
(Table 2). Ultimately, what conﬁrmed the diagnosis of CMV
was the positive IgM titer and a high viral load by polymerase

Table 2
Portal vein thrombosis and hepatitis laboratory studies.
Study
Ferritin
Iron
Transferrin
Iron saturation
PNH ﬂow cytometry
Antihepatitis A IgM
Antihepatitis B Core IgM
Hepatitis B surface antigen
Hepatitis C antibody
Hepatitis B viral load
Hepatitis C viral load
Carcinoembryonic antigen
Antismooth muscle antibody
Antimitochondrial antibody
Ceruloplasmin
Alpha-1-antitrypsin
Alpha-1-antitrypsin phenotype
Human immunodeﬁciency virus antibody and antigen
Epstein–Barr virus antigen IgG
Epstein–Barr virus antigen IgM
CMV virus IgG
CMV virus IgM
CMV quantitative PCR

Value

Normal range

6248 ng/mL
28 mg/dL
126 mg/dL
18%
Normal phenotyping results
No PNH clone is detected
Not detected
Intermediate
Not detected
1.09 Signal cutoff ratio
0 international units per milliliter
Not detected
0.8 ng/mL
<1:10 titer
<1:10 titer
32 mg/dL
61 mg/dL
SZ phenotype
Not detected
>3.50 IgG phospholipid units
0.22 IgM phospholipid units
>3.50 IgG phospholipid units
5.23 IgM phospholipid units
3220 international units per milliliter

22–274 ng/mL
31–144 mg/dL
174–364 mg/dL
15%–62%
Normal phenotyping results
No PNH clone is detected
Not detected
Not detected
Not detected
<1.0 signal cutoff ratio
0 international units per milliliter
Not detected
0.0–3.0 ng/mL
<1:10 titer
<1:10 titer
20–60 mg/dL
100–190 mg/dL
MM phenotype
Not detected
<0.90 IgG phospholipid units
<0.90 IgM phospholipid units
<0.90 IgG phospholipid units
<0.90 IgM phospholipid units
0 international units per milliliter

CMV = cytomegalovirus, PCR = polymerase chain reaction, PNH = paroxysmal nocturnal hematuria.
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Table 3
Additional laboratory studies.
Study
Peripheral blood smear
Blood cultures
Urinalysis
Stool culture
Clostridium difﬁcile PCR
Colonic biopsy, random

Thyroid stimulating hormone
Lyme antibody
Antinuclear antibody
Extracted nuclear antigen panel
Anticyclic citrullinated peptide antibody

Value

Normal range

∼10% atypical lymphocytes, rare smudge cells present, and
largely normal RBC morphology
No growth to date after 5 d
Normal
Negative
Negative
Colonic mucosa with prominent intramucosal lymphoid
aggregates. Negative for microscopic colitis. Trichrome
stain demonstrates normal subepithelial collagen thickness.
1.237 milli-international units per liter
0.44 immune status ratio
Negative
Negative
19 units

Normal
No growth to date after 5 d
Negative/normal
Negative
Negative
Normal mucosa

0.300–5.000 milli-international units per liter
<0.90 immune status ratio
Negative
Negative
<20 units

PCR = polymerase chain reaction, RBC = red blood cell.

4. Outcomes and follow-up

showed that between 1.9% and 9.1% of patients hospitalized with
VTE had concurrent acute CMV infection.[23]
Currently, the most plausible mechanism of CMV-induced
VTE involves formation of APS antibodies in response to CMV
infection with resulting transient hypercoagulable state. Several
case studies have described the formation of anticardiolipin
antibodies in acute CMV in humans.[24] In mice models, the
immunological pathways have been studied in greater detail.
Through this process, one CMV-derived peptide of particular
interest, TIFI, was found to be an analog of human beta-2glycoprotein I (b2GPI). Mice injected with TIFI developed APS
antibodies and measurable lupus anticoagulant activity, resulting
in more thrombotic events than controls.[25] Translation to
humans was postulated by formation of anti-b2GPI antibodies
against TIFI which would bind endogenous human b2GPI on the
surface of endothelial cells leading to activation of the
coagulation cascade.[26] This model was taken 1 step further
when it was demonstrated that injection of TIFI along with APS
antibodies had a protective effect from VTE in mice.[27] The
development of APS antibodies in patients with acute CMV
infection has not been consistently demonstrated in case studies,
but this appears to be a most promising avenue for further study.
Another possible mechanism involves the immune response to
accessible CMV envelope procoagulant phospholipids, such as

The patient continued to improve after discharge with only
anticoagulation. Ferritin and C-reactive protein trended down
and have since normalized. Anticoagulation was stopped after 6
months of therapy. Additional workup following discharge for
autoimmune disease, hypercoagulability including antiphospholipid syndrome (APS) and genetic mutations, and lyme disease
have been negative thus far (Tables 3 and 4). The resolution of his
fevers, diarrhea, hepatitis, and chronic fatigue is suggestive of full
viral clearance and completed seroconversion from IgM to IgG,
though this could not be conﬁrmed as the patient did not followup with the infectious disease specialist.

5. Discussion
When assessing the etiology of VTE, infectious causes such as CMV
are rarely considered. However, there is mounting evidence to the
contrary. At the time of preparing this case report, a literature review
of accessible sources revealed 28 cases documented in several case
reports and case series describing immunocompetent patients
presenting with CMV-induced VTE (Tables 5 and 6). Common
features included fever and abdominal pain. However, chronic
fatigue was very uncommon and none of the cases described a
prolonged prodrome of symptoms.[1–22] A recent meta-analysis

Table 4
Follow-up hypercoagulability studies.
Study
Factor II (prothrombin) Mutation
Factor V (leiden) mutation
MTHFR DNA mutation
Protein C activity
Protein S activity
Antithrombin III activity
Anticardiolipin IgG
Anticardiolipin IgM
Anticardiolipin IgA
Beta-2-glycoprotein IgG
Beta-2-glycoprotein IgM
Beta-2-glycoprotein IgA
Lupus anticoagulant

Value

Normal range

Normal
Normal
Negative
141%
72%
90%
3.8 IgG phospholipid antigen units per millilitre
6.5 IgM phospholipid antigen units per millilitre
1.8 IgA phospholipid antigen units per millilitre
11.1 IgG phospholipid antigen units per millilitre
8.1 IgM phospholipid antigen units per millilitre
2.8 IgA phospholipid antigen units per millilitre
Negative

Normal (homozygous wild-type)
Normal (homozygous wild-type)
Negative
79%–175%
65%–129%
82%–139%
0–11.9 IgG phospholipid antigen units per milliliter
0–11.9 IgM phospholipid antigen units per milliliter
0–9.9 IgA phospholipid antigen units per milliliter
<20.0 IgG phospholipid antigen units per milliliter
<20.0 IgM phospholipid antigen units per milliliter
<20.0 IgA phospholipid antigen units per milliliter
Negative

4

Kelkar et al. Medicine (2017) 96:51

www.md-journal.com

Table 5
Literature review (demographic and pertinent clinical characteristics of reported cases of venous thromboembolism occurring in the
context of acute cytomegalovirus infection in an immunocompetent host).
Article, y

Onset
(age)

Gender

Estival et al (2001)[1]
Ofotokun et al (2001)[2]
Abgueguen et al (2003)[3]
Abgueguen et al (2003)[3]
Youd et al (2003)[4]
Rovery et al (2005)[5]

31
50
32
38
35
33

F
M
F
F
M
M

Fever, lymphadenopathy
Fever, abdominal pain
Fever, dyspnea, left chest pain
Fever, diarrhea
Fevers, night sweats, weight loss
Fever, epigastric pain, RLE pain

PVT
PVT
DVT, PE
DVT, PE
PE
Tibial popliteal DVT

Paran et al (2007)[6]
Paran et al (2007)[6]

21
35

F
M

LLE pain
Fever, chest pain

Femoral popliteal DVT
Tibial popliteal DVT

Paran et al (2007)[6]
Squizzato et al (2007)[7]
Ergas et al (2008)[8]

29
34
28

F
M
M

Fever, dyspnea
Fever, cough
Fever, right ﬂank pain

Ladd et al (2009)[9]
Poon et al (2011)[10]
Kalaitzis et al (2012)[11]

17
30
40

F
F
M

Fever, RUQ abdominal pain
Fever, myalgia, cough
Fever, weight loss

Bilateral DVT
PVT
Mesenteric vein
thrombosis, PE
PVT, PE
PE
Mesenteric vein thrombosis

Heavy smoker, OCP
None
Factor V leiden (heterozygous)
None
NR
DVT history, factor V leiden
(heterozygous), strong family history
Positive anticardiolipin antibodies
Factor V leiden (heterozygous),
MTHFR mutation (Homozygous)
OCP
None
MTHFR (heterozygous),
strong family history
OCP
NR
None

Sherman et al (2012)[12]

70

M

FUO, headache

Sinus vein thrombosis

None

Presenting complaint

Hypercoagulable
state/risk factors

VTE location

Extra-vascular
manifestation
CMV
CMV
NR
CMV
CMV
CMV

Treatment

viremia, CMV hepatitis
viremia, splenomegaly
colitis
hepatitis
viremia

NR
Gancyclovir
NR
NR
NR
NR

NR
NR

NR
NR

NR
Splenomegaly
NR

NR
Warfarin
NR

NR
Splenic infarct
CMV viremia,
small bowel necrosis
NR

NR
Warfarin
Enoxaparin
Warfarin

APL = antiphospholipid antibodies, CMV = cytomegalovirus, DVT = deep vein thrombosis, F = female, FUO = fever of unknown origin, LLE = left lower extremity, M = male, NR = not reported, OCP = oral
contraceptive pills, PE = pulmonary embolism, PMH = past medical history, PVT = portal vein thrombosis, RLE = right lower extremity, VTE = venous thromboembolism.

be transient. This was demonstrated in case studies where there
was clearance of anticardiolipin antibodies several months after
CMV infection and acute VTE.[23] One prospective study
speciﬁcally described a window period of approximately
6-month postinfection where there appeared to a higher rate
of VTE than the control population.[30] This is especially
important in the context of the 2016 update to VTE guidelines
published by the American Thoracic Society, which called for
consideration of chronic anticoagulation in all patients with new,
unprovoked VTE.[31] If there is a subset of patients with transient
or reversible causes of hypercoagulability, we need to actively
identify them, as lifelong anticoagulation would be unnecessary
and potentially harmful.

phosphatidylserine. This would theoretically allow these compounds to bypass components of the coagulation cascade to
active thrombin through inhibition of innate anticoagulants.[28]
Alternatively, direct infection of endothelial cells by CMV has
long been suggested as the pathophysiology behind this
association of CMV with both venous and arterial thromboembolic events. This invokes Virchow triad, focusing on the role of
endothelial damage in thrombosis. In this model, infection of the
endothelial cells leads to lysis and release of tissue factormediated thrombin, inhibition and depletion of natural anticoagulants like antithrombin III, and inhibition of ﬁbrinolysis.[29]
Although one or more of the above mechanisms might be the
cause of this theoretical procoagulant state, the effect appears to

Table 6
Literature review (demographic and pertinent clinical characteristics of reported cases of venous thromboembolism occurring in the
context of acute cytomegalovirus infection in an immunocompetent host).
Article, y

Onset
(age)

Gender

Pichenot et al (2013)[13]
Pichenot et al (2013)[13]
Pichenot et al (2013)[13]
Galloula et al (2014)[14]
Nakayama et al (2014)[15]

39
40
43
24
19

Rinaldi et al (2014)[16]
Rinaldi et al (2014)[16]
Vandamme et al (2014)[17]

Hypercoagulable
state/risk factors

Presenting complaint

VTE location

M
F
F
F
M

Monosyndrome, abdominal pain
Diarrhea
Fever, purpura, arthralgia
NR
Fever, hemoptysis, right chest pain

PVT, PE
PVT
Bilateral DVT, PE
PVT
DVT, PE

None
OCP
Heavy smoking
OCP
APL

62
20
30

F
F
M

Fever, abdominal pain
Abdominal pain, headache
Fever, left chest pain, gastroenteritis

PVT
PVT
Bilateral PE

Smoker
None
None

Bertoni et al (2015)[18]

39

M

FUO, monosyndrome

Wang et al (2015)[19]

61

M

Chou et al (2016)[20]
Bountouris et al (2017)[22]
Vael et al (2017)[21]

78
25
58

M
M
F

Kelkar et al (2017)

46

M

Chronic fatigue, dyspnea,
night sweats, productive cough
Fever, diarrhea
Fever, cough, chest pain
Fever, abdominal pain,
chronic fatigue
FUO, abdominal pain,
emesis, diarrhea

Mesenteric vein
thrombosis
PVT

Extra-vascular
manifestation

Treatment
Warfarin, valgancyclovir
Warfarin
Warfarin, gancyclovir
Warfarin
Warfarin

Factor V leiden

CMV viremia
CMV viremia
None
NR
Alveolar hemorrhage,
CMV viremia
CMV hepatitis
CMV hepatitis
Myopericarditis, pulmonary
hemorrhage
NR

None

None

Warfarin

PE
DVT, PE
PVT

NR
None
None

CMV colitis
NR
CMV colitis

PVT

None

CMV viremia, suspected
CMV hepatitis,
suspected CMV colitis

Heparin, gancyclovir
rivaroxaban
Thrombolysis, right
hemicolectomy, heparin
warfarin

Warfarin, gancyclovir
Enoxaparin
NR
Warfarin

APL = antiphospholipid antibodies, CMV = cytomegalovirus, DVT = deep vein thrombosis, F = female, FUO = fever of unknown origin, LLE = left lower extremity, M = male, NR = not reported, OCP = oral
contraceptive pills, PE = pulmonary embolism, PMH = past medical history, PVT = portal vein thrombosis, RLE = right lower extremity, VTE = venous thromboembolism.
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embolism in a young immunocompetent adult infected with cytomegalovirus. Are novel oral anticoagulants an efﬁcient alternative? In Vivo
2017;31:1193–5.
[23] Justo D, Finn T, Atzmony L, et al. Thrombosis associated with acute
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antibodies. Semin Arthritis Rheum 2002;31:256–63.
[25] Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid
antibodies induced in mice by immunization with a cytomegalovirusderived peptide cause thrombosis and activation of endothelial cells in
vivo. Arthritis Rheum 2002;46:545–52.
[26] de Groot PG, Urbanus RT. The signiﬁcance of autoantibodies against b2glycoprotein I. Blood 2012;120:266–74.
[27] Ostertag MV, Liu X, Henderson V, et al. A peptide that mimics the vth
region of beta-2-glycoprotein I reverses antiphospholipid-mediated
thrombosis in mice. Lupus 2006;15:358–65.
[28] Pryzdial EL, Wright JF. Prothrombinase assembly on an enveloped virus:
evidence that the cytomegalovirus surface contains procoagulant
phospholipid. Blood 1994;84:3749–57.
[29] Squizzato A, Gerdes VEA, Buller HR. Effects of human cytomegalovirus
infection on the coagulation system. Thromb Haemost 2005;93:403–10.
[30] Paran Y, Shalev V, Steinvil A, et al. Thrombosis following acute
cytomegalovirus infection: a community prospective study. Ann
Hematol 2013;92:969–74.
[31] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE
disease: CHEST guideline and expert panel report. Chest 2016;149:
315–52.
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Keeping all of the above in mind, the combination of CMV
viremia and CMV hepatitis likely contributed to the procoagulant state, leading to PVT.[29,32] These features likely also
contributed to the prolonged debilitating fatigue prodrome,
which was a unique feature in this case, as it suggested a
prolonged failure to clear the virus, despite the patient’s
immunocompetent status. Although our patient did not require
antiviral therapy, further study into the possible beneﬁts of such
therapy in cases with immunocompetent patients is warranted.[33] We hope this case will support further study of the
mechanisms linking CMV to VTE and provide additional
testimony for consideration of acute CMV infection as a
procoagulant state by clinicians in practice. We are also planning
further study of our own in the form of retrospective analysis of
hypercoagulability in CMV patients and prospective testing for
CMV seropositivity in new cases of unprovoked VTE.

6. Methods
Informed consent from the patient was requested and obtained
from the patient. Ethical approval from our Institutional Review
Board was not necessary as this is a case report maintains the
anonymity of the patient.

7. Patient perspective
The patient was offered the option to share his written
perspective, but he politely refused the request. The authors
would like to thank our patient for allowing for his case to be
presented.
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